These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9293925)

  • 1. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b.
    Vermeulen PB; Dirix LY; Martin M; Lemmens J; Van Oosterom AT
    J Natl Cancer Inst; 1997 Sep; 89(17):1316-7. PubMed ID: 9293925
    [No Abstract]   [Full Text] [Related]  

  • 2. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas.
    Edgren M; Lennernäs B; Larsson A; Nilsson S
    Anticancer Res; 1999; 19(1B):869-73. PubMed ID: 10216508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
    Edgren M; Lennernäs B; Larsson A; Kälkner KM
    Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum vascular endothelial growth factor load and interleukin-6 in cancer patients.
    O'Byrne KJ; Dobbs N; Harris AL
    Br J Cancer; 2000 Jun; 82(11):1895-6. PubMed ID: 10839310
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum vascular endothelial growth factor is a candidate biomarker of renal cell carcinoma in hemodialysis patients.
    Ishizuka T; Hayashi T; Nakazawa H; Ito F; Nitta K; Horita S; Uchida K; Nihei H; Toma H
    Nephron; 2000 Jan; 84(1):83-4. PubMed ID: 10644915
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum angiogenic activity: diagnostic relevance in renal cell carcinoma.
    Beecken WD; Bentas W; Glienke W; Linneweber J; Jonas D; Binder J; Kramer W
    Eur Urol; 2002 Oct; 42(4):364-9. PubMed ID: 12361902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell carcinoma: relevance of angiogenetic factors.
    Wechsel HW; Bichler KH; Feil G; Loeser W; Lahme S; Petri E
    Anticancer Res; 1999; 19(2C):1537-40. PubMed ID: 10365140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.
    Hernberg M; Virkkunen P; Bono P; Ahtinen H; Mäenpää H; joensuu H
    J Clin Oncol; 2003 Oct; 21(20):3770-6. PubMed ID: 14551295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
    Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
    Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor platelet counts and renal cancer.
    Gunsilius E; Petzer AL; Gastl G
    Lancet; 1999 Jun; 353(9171):2247. PubMed ID: 10393017
    [No Abstract]   [Full Text] [Related]  

  • 13. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment.
    Nilsson A; Janson ET; Eriksson B; Larsson A
    Anticancer Res; 2001; 21(6A):4087-90. PubMed ID: 11911297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma.
    Sasamura H; Takahashi A; Miyao N; Yanase M; Masumori N; Kitamura H; Itoh N; Tsukamoto T
    Br J Cancer; 2002 Mar; 86(5):768-73. PubMed ID: 11875741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serologic angiogenesis factors and microvascular density in renal cell carcinoma: two independent parameters.
    Wechsel HW; Feil G; Bichler KH; Beiter T; Gleichmann R
    Anticancer Res; 2000; 20(6D):5117-20. PubMed ID: 11326680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor and basic fibroblast growth factor in melanoma.
    Weber F; Sepp N; Fritsch P
    Br J Dermatol; 2000 Feb; 142(2):392-3. PubMed ID: 10730793
    [No Abstract]   [Full Text] [Related]  

  • 17. Interferon alfa-2a tretinoin in patients with metastatic renal cell carcinoma: a pilot study.
    Paule B; Bonhomme-Faivre L; Rudant E; Ferrière F
    Am J Health Syst Pharm; 1997 Jan; 54(2):190-2. PubMed ID: 9117809
    [No Abstract]   [Full Text] [Related]  

  • 18. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer.
    O'Byrne KJ; Dobbs N; Propper D; Smith K; Harris AL
    Lancet; 1999 May; 353(9163):1494-5. PubMed ID: 10232320
    [No Abstract]   [Full Text] [Related]  

  • 19. Blood platelets and serum VEGF in cancer patients.
    Vermeulen PB; Salven P; Benoy I; Gasparini G; Dirix LY
    Br J Cancer; 1999 Jan; 79(2):370-3. PubMed ID: 9888483
    [No Abstract]   [Full Text] [Related]  

  • 20. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
    Jacobsen J; Rasmuson T; Grankvist K; Ljungberg B
    J Urol; 2000 Jan; 163(1):343-7. PubMed ID: 10604387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.